Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Cerebral and Cardiac Blood Flow During Exercise in Patients With COPD (REFLEX-COPD)

28 oktober 2019 bijgewerkt door: University of Nottingham

Cardiac Output and Brain Perfusion and Architecture During Exercise in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Healthy, Age Matched Volunteers

Heart disease and conditions related to the blood vessels are responsible for a large proportion (over a quarter) of the deaths in people with chronic obstructive pulmonary disease (COPD). The changes can also affect the smaller smaller blood vessels within the body, in particular the brain and the kidneys. This might be related to how the heart pumps and if it is under any pressure. Investigations performed at the University in healthy older volunteers demonstrated how the blood flows in the brain and heart during exercise. Exercise gently puts the whole body under some pressure and therefore exposes any weaker areas.

In this study the investigators are hoping to find out what happens to the blood flow in the brain and in the heart in patients who have COPD when they exercise and in the resting state. This will be compared to people of a similar age with a similar smoking history but without COPD. This will be examined using state of the art magnetic resonance imaging (MRI) and will allow us to assess whether changes in structure and function are related to this altered blood flow.

Our hypothesis is that COPD will cause a larger change in blood flow during exercise compared to the healthy volunteers and that reduced cardiorespiratory fitness will be associated with increased age related structural within the brain.

Studie Overzicht

Toestand

Onbekend

Gedetailleerde beschrijving

The aim is to recruit 20 participants with COPD, who will be compared to 10 age and gender matched controls who also have a smoking history. The investigators aim for this number to complete the components of the study and therefore may have to over-recruit if some people drop out or are not eligible. The study elements are feasible, as the work extends a previous research study in healthy volunteers.

This research trial will consist of a medical screening visit and three investigation study visits spaced ideally one week apart. The investigation visits will begin within 6 (ideally within 4) weeks of the medical screening visit. The total duration of the study and screening visits should be 12 weeks maximum for each participant.

Screening visit:

If the participant expresses an interest in the clinical trial and wants to take part they will be invited (at a convenient time for them) to attend a medical screening visit located at the Nottingham City hospital. Here the investigator will discuss the research trial and answer any questions or concerns they might have regarding the research trial. The participant, if willing, will then be required to sign a consent form so that the screening procedures can begin, which include:

  • Blood sample: Approximately a 20ml sample (4 teaspoons) taken from their arm, for further investigation including full blood count (FBC), brain natriuretic peptide (BNP) and kidney function.
  • Questionnaires: 5 different questionnaires that ask about symptoms and how they affect daily life, a physical activity questionnaire, quality of life questionnaire and a MRI safety questionnaire.
  • Spirometry: A simple blowing test to assess the participants' breathing which is performed three times.
  • 12 lead ECG.
  • a hand grip dynamometer to assess muscle strength
  • timed up and go test: a test used to measure gait speed, where participants are asked to get up from a chair and walking to 3 meters and back, whilst being timed.
  • to wear a step counter (Sensewear armband) for a week during waking hours to record steps.

Provided the ECG, step count (<10,000 steps) and other screening elements are ok, the participant will proceed to Study visit 1.

Strength and exercise test protocol:

The participant will be required to abstain from strenuous exercise for the 48 hours prior to the visit and also from alcohol and caffeine for 24 hours prior. Upon arrival they will perform a knee extension exercise so we can establish the muscle strength in the legs, specifically 3 maximal knee extensions with a 30 second rest in between. We will also measure fatigue by dong 20 extensions after a short break.

After a break they will then undergo an exercise test using an MRI compatible stepper device (Ergospect Cardiostepper) whilst in a supine position. This has been adapted to be similar to how they will exercise in the MRI scanner. Volunteers will start off stepping at a frequency of 65-70 steps a minute at the minimum workload and every 3 minutes get gradually a little harder until exhaustion is reached. Heart rate at rest and in response to exercise will be measured using a heart monitor. Participants will be given the option to have their expired gases also measured during exercise using a face mask, though this is not necessary if not tolerated. In the final minute of each workload we will take a finger prick test to measure the gases in the patients blood. A 3 lead ECG and oxygen saturation probe will be attached during exercise as safety measures and the protocol will be halted if oxygen saturation falls below 80% or if any relevant rhythm abnormalities are seen on the ECG trace.

The second study visit will be used to confirm the exercise and strength parameters measured in the first study visit.

MRI protocol:

A series of scans of the brain and heart will be taken at rest and then whilst stepping on the stepper machine within the MRI. The exercise will be at a steady state low level intensity determined by calculating the workload at which a fraction of maximum heart rate was achieved during first 2 study visits.

The MRI scan itself will take about ¾ hour but upto 2 hours is allowed for preparation and introducing the scan to the participant. The scanner is quite noisy and so the participant will wear ear defenders during the scan. Because the scanner is built around a large magnet, the participant will be instructed to remove all metal from their body, including jewellery. There is no radiation involved.

Studietype

Observationeel

Inschrijving (Verwacht)

30

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Nottinghamshire
      • Nottingham, Nottinghamshire, Verenigd Koninkrijk, NG5 1PB
        • Werving
        • NIHR Nottingham BRC Respiratory Theme, University of Nottingham and NUH Trust
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

60 jaar tot 75 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Kanssteekproef

Studie Bevolking

We are recruiting participants within the Nottinghamshire region. Specifically for patients with COPD, we are targeting outpatient respiratory clinics at the Nottingham University Hospitals Trust, inpatient admissions due to COPD exacerbation at the Nottingham City Hospital, pulmonary rehabilitation groups and respiratory focus groups within Nottingham and patients on the Nottingham Respiratory Research Unit database.

Beschrijving

Inclusion Criteria:

  • Patients aged 65-75 years old,
  • >10 pack years smoking,
  • FEV1/FVC <0.7 and FEV1<60% predicted (for COPD participants only)
  • Sedentary lifestyle (<10,000 steps per day)
  • Able to give informed consent
  • Able to read, understand and communicate coherently in English

Exclusion Criteria:

  • Doctor diagnosis of ischaemic heart disease or heart failure
  • Doctor diagnosis of dementia or Alzheimers disease
  • History of previous cerebrovascular disease (stroke or TIA) or malignancy
  • Pregnancy or childbearing in the last 6 months
  • Maintenance oral corticosteroids in the past 6 months
  • Requirement for oral corticosteroids or antibiotics in the past 6 weeks
  • Active arthritis or other muscular condition limiting exercise
  • Surgical intervention in the last 12 weeks
  • Long term oxygen therapy requirement
  • Other formal current respiratory diagnosis
  • Thyroid disease
  • Diabetes Mellitus
  • Neurological or cognitive impairment
  • Significant physical disability
  • Any other conditions in addition to the above that the investigators consider may affect study measurements or safety
  • Inability to understand verbal and/or written explanation of the study requirements

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: Case-control
  • Tijdsperspectieven: Dwarsdoorsnede

Cohorten en interventies

Groep / Cohort
Case
Participants with a pack year history of more than 10 pack years, diagnosed with COPD who have FEV1/FVC ratio of less than 0.7 AND FEV1 predicted value less than or equal to 60%.
Control
Participants without a diagnosis of COPD who have a smoking history of more than 10 pack years

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Resting white and grey matter structural integrity
Tijdsspanne: up to 12 weeks
Grey and white matter volume (mm3) using the MRI MPRAGE sequences will be measured at rest
up to 12 weeks
Cardiac structural integrity
Tijdsspanne: up to 12 weeks
Cardiac output (L/min) will be measured using the MRI sequence (Short axis Cine) at rest.
up to 12 weeks
Cardiac structural integrity
Tijdsspanne: up to 12 weeks
Cardiac fibrosis (%) will be measured using the MRI MOLLI T1 sequence at rest.
up to 12 weeks
Cardiac structural integrity
Tijdsspanne: up to 12 weeks
Myocardial strain (%) will be measured using the MRI cardiac tagging sequence at rest.
up to 12 weeks
Whole body fat and muscle quantification
Tijdsspanne: up to 12 weeks
Whole body fat and muscle quantification (%) will be measured using the MRI whole body mdixon sequence at rest.
up to 12 weeks
Aortic flow
Tijdsspanne: up to 12 weeks
Aortic flow (ml/min) will be measured during rest, low level steady-state exercise and following cessation of exercise and compared between COPD and age and gender matched controls
up to 12 weeks
Cerebral blood flow
Tijdsspanne: up to 12 weeks
Cerebral blood flow (ml/min) will be measured during rest, low level steady-state exercise and following cessation of exercise and compared between COPD and age and gender matched controls
up to 12 weeks
Cerebral perfusion
Tijdsspanne: up to 12 weeks
Cerebral artery perfusion (ml/100g/min) will be measured during rest, low level steady-state exercise and following cessation of exercise and compared between COPD and age and gender matched controls
up to 12 weeks
Oxygen extraction fraction
Tijdsspanne: up to 12 weeks
Oxygen extraction fraction (%) will be derived from the difference between arterial and venous cerebral oxygenation measured via TRUST MRI scan sequence during rest, low level steady-state exercise and following cessation of exercise and compared between COPD and age and gender matched controls
up to 12 weeks

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Muscle isometric strength (MVC)
Tijdsspanne: up to 6 weeks
Isometric muscle torque of the quadriceps (Nm) assessed using the cybex dynamometer
up to 6 weeks
Muscle isokinetic fatigue
Tijdsspanne: up to 6 weeks
Fatiguability test of the quadriceps (Nm) assessed using the cybex dynamometer
up to 6 weeks
Quality of life (SGRQ)
Tijdsspanne: 1 week
Assessed using the St Georges Respiratory Questionnaire. min value: 0, max value: 84, higher score means worse outcome
1 week
Physical activity level (IPAQ Physical activity questionnaire)
Tijdsspanne: 1 week
Assessed using the International Physical activity questionnaire. min value: 0, max value: 66000, higher score means better outcome
1 week
Montreal Cognitive Assessment (MoCA) cognition level
Tijdsspanne: 1 week
Assessed using the Montreal cognitive assessment questionnaire. min value: 0, max value: 30, higher score means better outcome
1 week
Hospital anxiety and depression scale (HADS)
Tijdsspanne: 1 week
min value: 0, max value: 21, higher score means worse outcome
1 week
Hand grip strength
Tijdsspanne: 1 week
Composite of hand grip strength (Kg), measured by a hand held dynamometer,
1 week
Timed up and go test
Tijdsspanne: 1 week
Timed up and go test (seconds) will be measured to assess degree of frailty.
1 week
Serum markers of inflammation for research purposes (likely to include IL-1, IL-6, and TNFα)
Tijdsspanne: 1 week
Blood test
1 week
Heart rate response to exercise
Tijdsspanne: up to 6 weeks
Heart rate response (Beats per minute) will be measured at rest and during incremental exercise to assess cardio-respiratory fitness.
up to 6 weeks

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Charlotte Bolton, NIHR Nottingham Biomedical Research Centre Respiratory theme, University of Nottingham

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

3 januari 2019

Primaire voltooiing (Verwacht)

30 september 2020

Studie voltooiing (Verwacht)

30 september 2020

Studieregistratiedata

Eerst ingediend

17 oktober 2019

Eerst ingediend dat voldeed aan de QC-criteria

22 oktober 2019

Eerst geplaatst (Werkelijk)

24 oktober 2019

Updates van studierecords

Laatste update geplaatst (Werkelijk)

30 oktober 2019

Laatste update ingediend die voldeed aan QC-criteria

28 oktober 2019

Laatst geverifieerd

1 oktober 2019

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

Onbeslist

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren